Cargando…
Beyond Antibodies: The DARPin(®) Drug Platform
The DARPin(®) drug platform was established with a vision to expand the medical use of biologics beyond what was possible with monoclonal antibodies. It is based on naturally occurring ankyrin repeat domains that are typically building blocks of multifunctional human proteins. The platform allows fo...
Autores principales: | Stumpp, Michael T., Dawson, Keith M., Binz, H. Kaspar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312107/ https://www.ncbi.nlm.nih.gov/pubmed/32583318 http://dx.doi.org/10.1007/s40259-020-00429-8 |
Ejemplares similares
-
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
por: Stahl, Andreas, et al.
Publicado: (2012) -
MP0250, a VEGF and HGF neutralizing DARPin(®) molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
por: Fiedler, Ulrike, et al.
Publicado: (2017) -
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
por: Baird, Richard D., et al.
Publicado: (2021) -
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
por: Rothenberger, Sylvia, et al.
Publicado: (2022) -
DARPins: Promising Scaffolds for Theranostics
por: Shilova, O. N., et al.
Publicado: (2019)